Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718038 | 0.90 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL713514 | 0.82 | PIK3CD (0.48) | PIK3CD | |
| SCHEMBL17530807 | 0.82 | PIK3CD (0.58) | PIK3CD | |
| SCHEMBL716764 | 0.80 | PIK3CD (0.48) | PIK3CD | |
| SCHEMBL17530809 | 0.79 | PIK3CD (0.40) | PIK3CD | |
| SCHEMBL715530 | 0.75 | PIK3CD (0.39) | PIK3CD | |
| SCHEMBL716993 | 0.74 | PIK3CD (0.50) | PIK3CD | |
| SCHEMBL2115560 | 0.74 | ALDH1A1 (0.56) | FAAH | |
| SCHEMBL10081 | 0.72 | PIK3CD (0.42) | PIK3CDFAAH | |
| SCHEMBL713702 | 0.72 | PIK3CD (0.53) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | PIK3CD 12/4885FAAH 1270/4885 |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | PIK3CD 6/4885FAAH 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.